Glycomics Market - Forecasts from 2022 to 2027

The Glycomics Market is evaluated at US$1,174.889 million for the year 2020, growing at a CAGR of 8.63%, reaching the market size of US$2,096.655 million by the year 2027.

Glycomics is the comprehensive study of glycomes, including genetic, physiologic, pathological, and other aspects. It refers to the study of all the glycan structures of a given cell type or organism in a systematic manner. The global glycomics market is anticipated to propel at a noteworthy CAGR primarily attributable to the growing research activities in glycomics in many parts of the world. Additionally, the profitable investments by pharmaceutical companies in research and development activities also play a significant role in shaping the market growth over the forecast period. Moreover, increased government support for R&D in drug discovery and development coupled with the growth in proteomics research studies will bolster the demand for glycomics products shortly, thus positively impacting the growth over the next five years. Additionally, governments around the globe, particularly in developing economies, are further enabling academic researchers to expand their knowledge in the field and develop new tools and products to promote the field of glycoscience. This, in turn, augments the business growth opportunities for the market players shortly.

Covid-19 Impact

Biotechnology and pharmaceutical organizations are working together with government agencies to mitigate the COVID-19 pandemic by developing vaccines to planning for supply chain challenges in delivering those to the masses. Furthermore, commonly used drugs like hydroxychloroquine have significantly improved COVID-19 governance. Because many developed countries are running out of these drugs, their prominence has created a huge opportunity to develop COVID-19 governance drugs. Because of the high demand for COVID-19 vaccines and treatment drugs, the pharmaceutical and biotechnology industries and their research and development for new medications are expected to grow significantly. Because of these factors, COVID-19 had a significant positive impact on the Glycomic market. It is used for many research and development of drugs, especially in cases related to the diabetic population. The outbreak of the novel coronavirus disease is anticipated to have a significant impact on market growth since companies are striving hard to address the impact of this disease. Companies are expanding their R&D budgets and are working round the clock since the demand for commonly used drugs is significantly high in many countries. This, in turn, is boosting the pharmaceutical and biotechnology industry since the duration of this pandemic is still uncertain.

Key Developments in the market:

A significant volume of companies are working in the glycomics market; however, some have solidified their position as the leading providers in this industry. These players are involved in a plethora of investments, product launches, and R&D as a part of their growth strategies to strengthen their position further and provide better products and services to their customers worldwide, which is expected to propel the market's growth in the coming years. Some of these are:

In April 2022, GlycoNet, a leading global in glycomics research and drug development, has declared a $1.73 million investment in 13 glycomics projects across Canada. Health foundations, Industry partners, and business partners had also contributed US$5.97 million, bringing the total funding to $7.7 million. This fundraising will go toward research that will help patients with cancer, chronic diseases, infectious diseases, and neurodegenerative disorders live better lives.

In July 2020, GlycoNet, a Canadian network of excellence centred at UAlberta, received an investment worth US$16.3 million, enabling it to continue its mission to research glycomics to benefit human health.

In July 2020, GlycoNet awarded grant funding worth US$3.9 to 11 collaborative research projects, which will support a wide range of multidisciplinary research teams across 17 Canadian research projects to address their needs in numerous diseases such as cancer, and gastrointestinal inflammations, and cystic fibrosis, among others.

In May 2020, Pneumagen Ltd., a UK-based company engaged in treating infectious diseases by targeting the human glycome, announced that they raised £4 million, which was led by Chairman Bio (Thairm) with participation from the Scottish Investment Bank (SIB).

The glycomics market has been segmented based on product, application, and geography. Based on product, the market classification has been done into enzymes, instruments, kits, and others. The market has been segmented based on drug discovery, diagnostics, and others by application. Geographically, the market has been distributed in North America, South America, Europe, the Middle East and Africa, and the Asia Pacific.

Instruments to hold a significant market share.

By product, the instruments segment is expected to hold a significant share in the market throughout the next five years due to its vast and frequent applications in drug discovery and diagnostic testing. The enzymes segment will witness considerable growth during the forecast period due to their consumable nature. Moreover, the wide application of enzymes in numerous drug discovery procedures is one of the prime factors for the significant share of this segment in the glycomics market during the next five years. The kits segment is also projected to show robust growth during the next five years, which may be on account of their frequent usage.

Drug discovery to witness significant growth.

By application, the drug discovery segment is expected to propel at a healthy compound annual growth rate during the next five years. The extensive government support and increased focus of pharma companies, coupled with the growing prevalence of chronic diseases, are some of the key factors propelling the activities in the drug discovery segment by major pharmaceutical companies that play a crucial role in shaping the growth of this segment during the next five years.

North America to hold a considerable share.

Regionally, North America is anticipated to hold a considerable market share. The presence of major pharmaceutical and biopharmaceutical companies, including the region, and world-class infrastructure are some of the leading factors supporting the share of this segment during the next five years. Additionally, significant government support and factors such as high technology adoption are some of the additional factors for the high share of North America in the global market. However, the Asia Pacific region is anticipated to witness decent growth during the next five years because of the booming pharmaceutical and biopharmaceutical industries in countries like India and China.

Competitive Insights

The players in the glycomics market are implementing various growth strategies to gain a competitive advantage over their competitors in this market. Major market players have been covered along with their relative competitive strategies. The report also mentions recent deals and investments of different market players over the last few years. The company profiles section details the business overview, financial performance (public companies) for the past few years, key products and services being offered, and the recent deals and investments of these important players in the glycomics market.

Segmentation

By Product

• Enzymes
• Instruments
• Kits

By Application

• Drug Discovery
• Diagnostics

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Europe
• Germany
• France
• UK
• Middle East and Africa
• Saudi Arabia
• UAE
• Asia Pacific
• China
• Japan
• India
• South Korea
• Taiwan
• Thailand
• Indonesia